Amplifon stock reports stronger Q3 margins as GN Hearing deal advances

Amplifon reported stronger profitability in the third quarter of 2026, with organic growth reaching 3.6% despite the highest comparison base of the year. The company published the results on October 29, 2026, in its Q3 2026 results release.

Amplifon stock traded at 12.31 euros on Lang & Schwarz at 10:40 CET on Monday, November 9, 2026. Investors can follow the real-time quote of Amplifon stock.

Profitability improves across the group

Quarterly adjusted EBITDA rose 7.0%, while the margin expanded by 90 basis points. Adjusted EBIT increased 21.9%, with the margin widening by 150 basis points to 9.1%. Adjusted net profit grew 38.7% in the quarter. Management attributed the improvement to operating leverage and the Fit4Growth program.

For the first nine months, revenue reached 1,760.8 million euros, up 0.9% at constant exchange rates. Organic growth stood at 3.5%, while adjusted EBITDA rose 4.5% to 412.8 million euros and the margin reached 23.4%, an increase of 80 basis points. Adjusted EBIT advanced 11.5% to 222.0 million euros, and adjusted net profit increased 16.9% to 128.2 million euros.

Cash generation and restructuring support

Adjusted free cash flow climbed 138.6% to 79.1 million euros in the first nine months, after capital expenditure of 64.3 million euros. Pro forma net financial debt stood at 1,052.8 million euros at September 30, 2026, compared with 1,045.5 million euros at the end of 2025, while financial leverage improved to 1.85 times.

The Fit4Growth program reduced reported revenue growth by 3.3% in the first nine months. Amplifon said the program includes efficiency measures such as the divestment of the Indian and UK businesses, the termination of a managed-care agreement in the United States and the closure of non-performing clinics. The company presents adjusted figures excluding unusual, infrequent or unrelated items outside normal operations.

GN Hearing remains the strategic focus

Chief Executive Enrico Vita said planning for the integration of GN Hearing was progressing according to schedule, with the company aiming to be ready when the acquisition closes. The transaction is expected to strengthen Amplifon's position across hearing-care retail and related services, but completion remains the key execution milestone for investors.

Amplifon confirmed its 2026 outlook for organic growth above 3% and an adjusted EBITDA margin increase in the region of 100 basis points. The outlook gives investors a reference point for judging whether the margin gains from operating leverage and Fit4Growth can continue while the group prepares for the GN Hearing transaction.

The broader market backdrop can be followed in current market reports.

Further details on the company and its results are available in more news and analyses on Amplifon stock.